Immunocore Holdings plc Research and Development Expense
Immunocore Holdings plc (IMCR) reported Research and Development Expense of $73.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Immunocore Holdings plc research and development expense for the quarter ending 2026-06-30 was $73.94M, a 7.15% increase year-over-year.
- Immunocore Holdings plc research and development expense for the quarter ending 2026-03-31 was $61.11M, a 8.23% increase year-over-year.
- Immunocore Holdings plc research and development expense for the quarter ending 2025-12-31 was $78.82M, a 29.53% increase year-over-year.
- Immunocore Holdings plc research and development expense for the quarter ending 2025-09-30 was $70.57M, a 33.74% increase year-over-year.
- Immunocore Holdings plc research and development expense for fiscal 2025 was $274.87M, a 23.73% increase from fiscal 2024.
- Immunocore Holdings plc research and development expense for fiscal 2024 was $222.15M, a 35.83% increase from fiscal 2023.
- Immunocore Holdings plc research and development expense for fiscal 2023 was $163.54M, a 60.46% increase from fiscal 2022.
- Immunocore Holdings plc research and development expense for fiscal 2022 was $101.92M, a 1.67% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $73.94M 10-Q · filed 2026-08-06 | $135.06M 10-Q · filed 2026-08-06 | $213.88M derived: sum of 3 quarters · filed 2026-08-06 | $284.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $61.11M 10-Q · filed 2026-05-06 | $139.93M derived: sum of 2 quarters · filed 2026-05-06 | $210.51M derived: sum of 3 quarters · filed 2026-05-06 | $279.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $78.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $149.39M derived: sum of 2 quarters · filed 2026-02-25 | $218.40M derived: sum of 3 quarters · filed 2026-08-06 | $274.87M 10-K · filed 2026-02-25 |
| 2025-09-30 | $70.57M 10-Q · filed 2025-11-06 | $139.58M derived: sum of 2 quarters · filed 2026-08-06 | $196.05M 10-Q · filed 2025-11-06 | $256.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $69.01M 10-Q · filed 2026-08-06 | $125.48M 10-Q · filed 2026-08-06 | $186.33M derived: sum of 3 quarters · filed 2026-08-06 | $239.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $56.47M 10-Q · filed 2026-05-06 | $117.32M derived: sum of 2 quarters · filed 2026-05-06 | $170.09M derived: sum of 3 quarters · filed 2026-05-06 | $221.16M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $60.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $113.62M derived: sum of 2 quarters · filed 2026-02-25 | $164.69M derived: sum of 3 quarters · filed 2026-02-25 | $222.15M 10-K · filed 2026-02-25 |
| 2024-09-30 | $52.77M 10-Q · filed 2025-11-06 | $103.84M derived: sum of 2 quarters · filed 2025-11-06 | $161.30M 10-Q · filed 2025-11-06 | $206.87M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $51.07M 10-Q · filed 2025-08-07 | $108.53M 10-Q · filed 2025-08-07 | $154.10M derived: sum of 3 quarters · filed 2026-02-25 | $197.34M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $57.46M 10-Q · filed 2025-05-07 | $103.02M derived: sum of 2 quarters · filed 2026-02-25 | $146.27M derived: sum of 3 quarters · filed 2026-02-25 | $184.43M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $45.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $88.81M derived: sum of 2 quarters · filed 2026-02-25 | $126.97M derived: sum of 3 quarters · filed 2026-02-25 | $163.54M 10-K · filed 2026-02-25 |
| 2023-09-30 | $43.25M 10-Q · filed 2024-11-06 | $81.41M derived: sum of 2 quarters · filed 2024-11-06 | $117.98M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $38.16M 10-Q · filed 2024-08-08 | $74.73M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $36.57M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $101.92M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $100.25M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |